Combination therapy doubles one-year survival in pancreatic cancer trial Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer Written byBree Foster, PhD

https://www.drugdiscoverynews.com/combination-therapy-doubles-one-year-survival-in-pancreatic-cancer-trial-17121?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--yRcIW3ePhLMY2_WOsAD1LLfawJJr0jh_EmEi2ySeKxLdBWzsqNaIXpFIGhno8Uttcn6b1P0z7acRZBKt4tOe3u2S6MA&_hsmi=427883198&utm_content=427883198&utm_source=hs_email A drug developed at Northwestern University has shown a promising survival advantage in patients with metastatic pancreatic cancer, a disease that remains among the deadliest solid tumours and is projected to become the second leading cause of cancer-related deaths in the US within the next decade.